Marek H.
- Country
- Poland
- Department
- Endoskopia sp. z o.o.
Research Overview
- Safety Evaluation of SOR102 in Healthy Subjects and Ulcerative Colitis Patients: A Phase I Clinical Trial
- Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Duvakitug for Induction Therapy in Moderately to Severely Active Crohn's Disease
- Efficacy and Safety of Duvakitug for Maintenance Therapy in Participants with Moderately to Severely Active Crohn’s Disease: A Phase 3, Randomized, Placebo-Controlled Study
Data & Insights
Has run more than one trial at 391 of 597 partner sites.
Specializations
Inflammatory Bowel Disease
The investigator is closely involved in clinical research on inflammatory bowel disease, with a strong emphasis on ulcerative colitis and Crohn’s disease. The trial portfolio reflects sustained interest in disease control, symptom relief, and mucosal and endoscopic outcomes across active and recurrent gastrointestinal inflammation.
- Ulcerative colitis
- Crohn’s disease
- Endoscopic response
- Clinical remission
Research activity also extends to difficult-to-manage forms of IBD, including moderately to severely active disease and fibrostenotic complications.
Targeted Immunotherapy
A major therapeutic focus is the evaluation of targeted immunotherapy for immune-mediated intestinal disease. The investigator participates in studies of agents designed to modulate inflammatory pathways relevant to chronic mucosal inflammation and immune dysregulation.
- Immune-mediated inflammation
- Targeted biologic therapy
- Maintenance treatment
- Induction of remission
The therapeutic landscape includes advanced biologic therapies and other precision approaches aimed at improving control of refractory ulcerative colitis and Crohn’s disease.
Gastrointestinal Motility Disorders
In addition to inflammatory disorders, the investigator is engaged in research on gastroparesis, particularly idiopathic and diabetic gastroparesis. This area reflects interest in upper gastrointestinal motility and the management of chronic symptoms related to delayed gastric emptying.
- Gastroparesis
- Diabetic gastrointestinal disease
- Upper digestive motility
- Symptom burden
These studies broaden the therapeutic scope beyond colonic inflammation to include functional disorders of the digestive tract.
Hepatology and Metabolic Liver Disease
The investigator also contributes to clinical research in hepatology, with attention to chronic viral hepatitis B, alcoholic liver disease, and metabolic dysfunction-associated steatotic liver disease / MASH. This area highlights involvement in chronic liver injury and metabolic liver inflammation.
- Chronic viral hepatitis B
- Alcoholic liver disease
- MASLD
- MASH
Research in this field connects inflammatory and metabolic pathways with long-term liver disease management.
Immune-Mediated Disease
Clinical trial involvement also includes broader immune-mediated diseases, indicating interest in systemic inflammatory conditions that overlap with gastrointestinal autoimmunity. This domain supports investigation of therapies aimed at immune regulation across chronic disease states.
- Immune system diseases
- Chronic inflammatory disorders
- Therapeutic immune modulation
- Inflammation-driven pathology
The research profile is centered on medical innovation in disorders where immune activation is a major therapeutic target.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.